资源类型

期刊论文 1

年份

2019 1

关键词

检索范围：

排序： 展示方式：

Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia

Weina Zhang, Ying Lu, Tao Zhen, Xinjie Chen, Ming Zhang, Ping Liu, Xiangqin Weng, Bing Chen, Yueying Wang

《医学前沿（英文）》 2019年 第13卷 第3期   页码 388-397 doi: 10.1007/s11684-018-0624-1

摘要： Collaboration of c-KIT mutations with AML1–ETO (AE) has been demonstrated to induce t(8; 21) acute myeloid leukemia (AML). Targeted therapies designed to eliminate AE and c-KIT oncoproteins may facilitate effective treatment of t(8; 21) AML. Homoharringtonine (HHT) features activity against tumor cells harboring c-KIT mutations, whereas oridonin can induce t(8; 21) AML cell apoptosis and AE cleavage. Therefore, studies should explore the efficacy of combination therapy with oridonin and HHT in t(8; 21) AML. In this study, we investigated the synergistic effects and mechanism of oridonin combined with HHT in t(8; 21) AML cell line and mouse model. The two drugs synergistically inhibited cell viability and induced significant mitochondrial membrane potential loss and apoptosis. Oridonin and HHT induced significant downregulation of c-KIT and its downstream signaling pathways and promoted AE cleavage. HHT increased intracellular oridonin concentration by modulating the expressions of MRP1 and MDR1, thus enhancing the effects of oridonin. The combination of oridonin and HHT prolonged t(8; 21) leukemia mouse survival. In conclusion, oridonin and HHT exert synergistic effects against t(8; 21) leukemia and , thereby indicating that their combination may be an effective therapy for t(8; 21) leukemia.

关键词： AML1–ETO     c-KIT     homoharringtonine     oridonin     t(8     21) AML     synergistic effect    

HTML PDF 收藏

标题 作者 时间 类型 操作

Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia

Weina Zhang, Ying Lu, Tao Zhen, Xinjie Chen, Ming Zhang, Ping Liu, Xiangqin Weng, Bing Chen, Yueying Wang

期刊论文